Market Feasibility Study of Dexlansoprazole

Abstract

Dexlansoprazole, an enantiomer of Lansoprazole, is a proton pump inhibitor, which irreversibly blocks the hydrogen/potassium adenosine triphosphatase enzyme system (the H+/K + ATPase, or more commonly just gastric proton pump) of the gastric parietal cell. The purpose of this study is to analyze the market feasibility study of Dexlansoprazole and to launch Dexlansoprazole in Bangladesh pharma market. Many books, journals, articles were also used to know efficacy and safety profile of drugs. International Market Strategy (IMS) data was used to determine the market size. Dexlansoprazole gives prolonged action which is almost double than Lansoprazole. It shows better efficacy in erosive oesophagitis, GERD, NERD than the other proton pump inhibitor. Therefore, the total market size of Dexlansoprazole will be increased and it will capture the Rabeprazole, Esomeprazole and Pantoprazole. The estimated market size for Dexlansoprazole is 11.0 crore taka and the estimated growth rate for Dexlansoprazole is 10-12% in the next year. So it is better to launch Dexlansoprazole in the next year.